NOVKAN Share Price Performance
SEK 0.21
-1.49 (-87.57%)
Price SEK 0.21
Share PriceSEK 0.21
Novakand Pharma AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
NOVKAN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Novakand Pharma AB (publ) Key Details
About NOVKAN
- Founded
- 2010
- Employees
- 5
- CEO
- WebsiteView website
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025. Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
